CONSHOHOCKEN, PA — Madrigal Pharmaceuticals, Inc. (NASDAQ: MDGL) has released a business update highlighting strong preliminary financial results for 2024 and the ongoing success of its ...

Analyst Mayank Mamtani from B.Riley Financial reiterated a Hold rating on Madrigal Pharmaceuticals ... financial and operational performance. The company’s recent sales figures for Rezdiffra ...

Madrigal Pharmaceuticals provided an update on its financial performance, revealing preliminary fourth-quarter and full-year 2024 net sales for Rezdiffra™ (resmetirom) projected between $100 ...

Madrigal Pharmaceuticals, Inc. engages in the development and commercialization of innovative therapeutic candidates for the treatment of cardiovascular, metabolic, and liver diseases. Its lead ...

Investors often closely monitor such transactions for insights into executive sentiment and potential impacts on stock performance. Madrigal Pharmaceuticals specializes in pharmaceutical ...

Shares of Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL – Get Free Report) have earned a consensus recommendation of “Moderate Buy” from the thirteen analysts that are presently covering the stock, ...

The major league portion of the contract is worth $1.35 million, according to The Post’s Joel Sherman, and contains another $500,000 in performance bonuses. Madrigal, 27, spent the last three ...

Equities researchers at Leerink Partnrs reduced their FY2026 earnings per share estimates for shares of Madrigal Pharmaceuticals in a note issued to investors on Wednesday, February 5th. Leerink ...

In trading on Tuesday, shares of Madrigal Pharmaceuticals Inc (Symbol ... The chart below shows the one year performance of MDGL shares: Looking at the chart above, MDGL's low point in its ...

13, 2025 (GLOBE NEWSWIRE) -- Madrigal Pharmaceuticals ... steatohepatitis (MASH), today announced an update on its business performance, including preliminary* fourth-quarter and year-end net ...